GlassScriptPhysician profile
Peter A Eweje
NPI 1871538363
$517.66
in general payments reported to CMS, 2019-2025
13 companies · $47.02 in 2025
The $47.02 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $27.86 · 2022: $22.24 · 2023: $86.69 · 2024: $19.10 · 2025: $47.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $105.72 | 2019-2020 | |
| Dova Pharmaceuticals | $97.69 | 2019 | |
| Shionogi INC | $93.22 | 2019 | |
| Gilead Sciences, INC. | $85.76 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $47.02 | 2025 | Iqirvo |
| Boston Scientific Corporation | $20.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.10 | 2024 | Voquezna |
| Janssen Biotech, INC. | $18.53 | 2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.47 | 2023 | Trulance, Uceris |
| Ironwood Pharmaceuticals, INC | $12.88 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Eweje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.